Stereotaxis Receives Regulatory Approval of Niobe(R) Technology in Japan; Begins Commercialization Efforts

Stereotaxis Receives Regulatory Approval of Niobe(R) Technology in Japan;
Begins Commercialization Efforts

ST. LOUIS, March 25, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced today that it has received regulatory approval of its Niobe® remote
magnetic technology for cardiac ablations in Japan, a critical milestone in
securing full market entry into the country. This approval allows the Company
to begin marketing efforts, including establishing a local business
infrastructure with in-country distributors, while working on obtaining
reimbursement approval for full market entry, or the ability to initiate
sales. Reimbursement approval is expected by the end of 2013.

Approval by the Pharmaceuticals and Medical Devices Agency, Japan's equivalent
to the U.S. Food and Drug Administration, follows a successful three-year
clinical trial of the Niobe system at the Tokyo Women's Medical University.
The clinical trial was led by Dr. Morio Shoda and supported by the Company's
industry collaborators in Japan.

William Mills, Chairman of the Stereotaxis Board of Directors, says the
Japanese market, the second largest for medical devices behind the U.S.,
represents a significant growth opportunity for the Company. "An aging
population, prominent cardiovascular institutions that embrace new
technologies and favorable, universal health coverage create a very attractive
environment for us to leverage our one-of-a-kind robotic navigation system,"
says Mr. Mills. "Our entry into Japan provides opportunity for meaningful
growth in the Asia Pacific region and marks a major step towards our vision of
becoming the first choice in the treatment of complex electrophysiology
ablations for the global marketplace." 

There are currently 570 hospitals in Japan performing approximately 38,000
electrophysiology (EP) procedures annually, 45% of which are atrial
fibrillation (AF) cases. With the highest life expectancy among developed
nations – 82.9 years – Japan has a rapidly growing senior population,
currently at 23% and expected to reach 40% in the next 50 years. As AF and
other arrhythmias are typically present in older individuals, the rate of EP
ablations is anticipated to rise with the aging population. By 2018, industry
analysts expect the country to experience 12% annual growth in EP procedures
and a 22% annual increase in AF cases.

Mr. Mills adds that the Niobe's demonstrated strength in significantly
reducing radiation exposure to physicians and patients will be particularly
appealing to a Japanese society highly sensitive to radiation risk. The
Company looks forward to showcasing its Niobe technology for prospective
Japanese clients at the annual Heart Rhythm Society (HRS) scientific session
in May and the Japanese HRS meeting in July.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core
technologies are the Niobe^® ES Remote Magnetic Navigation system, the
Odyssey^® portfolio of lab optimization, networking and patient information
management systems and the Vdrive^™ Robotic Mechanical Navigation system and
consumables.

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Loop^™ circular catheter
manipulator is currently in clinical trials in order to obtain clearance by
the U.S. Food and Drug Administration; the Company also is pursuing U.S.
clearance for the V-Sono™ ICE catheter manipulator. For more information,
please visit www.stereotaxis.com and www.odysseyexperience.com.

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, our continued access to
capital and financial resourceson a timely basis and on terms that are
acceptable, our continued listing on the Nasdaq Global Market, continued
acceptance of the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to purchase
our systems and the timing of such purchases, the outcome of various
shareholder litigation recently filed against us, competitive factors, changes
resulting from the recently enacted healthcare reform in the U.S., including
changes in government reimbursement procedures, dependence upon third-party
vendors, timing of regulatory approvals, and other risks discussed in the
Company's periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the
date of this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders and other
commitments are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.

CONTACT: Press Contact:
         Frank Cheng
         Senior Vice President, Marketing and
         Business Development
         314-678-6111
        
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300